News | September 07, 2021
Indian Pharmaceutical Market grew by 17.7 per cent in August
Ind-Ra expects IPM revenue to grow over 12% YoY in FY22
Ind-Ra expects IPM revenue to grow over 12% YoY in FY22
The focus is on wellness and personal care products
At present 18 per cent of the local pharmaceutical market is under government's price control
The segment delivered strong sales growth of 20% YoY
Domestic business was up 41.9% YoY and 27.7% QoQ
Demand normalisation post the second wave contributed to the steady growth
Adjusted PAT declined 18.8% YoY
In animal health, the products will be mainly targeting mastitis and production disorders, gastrointestinal tract diseases, reproductive disorders, ectoparasites, and skin injuries
The company also plans to register the similar range of products in the neighbouring countries.
174 applications were received for 23 eligible products under Target Segment IV - Other Chemical Synthesis Based KSMs/ Drug Intermediates/APIs.
Subscribe To Our Newsletter & Stay Updated
